Novynette (Desogestrel, Ethinylestradiol)

Novynette is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle.

• Contraception: Provides effective prevention of pregnancy when taken as directed.
• Menstrual cycle regulation: Helps to achieve more predictable bleeding patterns.
• Acne improvement: Reduces androgen‑related skin lesions in some users.

• Novynette combines desogestrel, a third‑generation progestogen that binds to progesterone receptors and suppresses luteinising hormone surge, with ethinylestradiol, a synthetic estrogen that provides negative feedback on the hypothalamic‑pituitary‑gonadal axis. Together they inhibit ovulation, thicken cervical mucus and modify the endometrium, creating multiple mechanisms that prevent fertilisation.

Novynette may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild stomach upset that usually resolves with continued use.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: temporary swelling or discomfort.
• Weight gain: slight increase in body weight, often fluid‑related.
• Mood changes: irritability or emotional lability.
• Spotting between periods: light vaginal bleeding.

Serious or Rare Side Effects

• Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
• Arterial thrombosis: stroke or myocardial infarction.
• Severe hypertension: sudden, marked increase in blood pressure.
• Liver dysfunction: jaundice or abnormal liver enzymes.
• Allergic reaction: rash, itching, swelling or anaphylaxis.

Before prescribing Novynette, clinicians should assess individual risk factors and counsel patients on safe use.

• Smoking status: avoid use in women over 35 who smoke.
• Cardiovascular history: assess for hypertension, clotting disorders or heart disease.
• Migraine history: caution in patients with migraine with aura.
• Liver function: evaluate hepatic impairment before initiation.
• Pregnancy and lactation: contraindicated during pregnancy; advise breastfeeding women of potential risks.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Novynette can interact with several medicines that affect its metabolism or clotting risk.

Major Interactions (Avoid)

• Antifungal azoles (ketoconazole, itraconazole): increase estrogen levels and thrombosis risk.
• Antiretroviral protease inhibitors (ritonavir): elevate plasma concentrations of both hormones.
• Strong CYP3A4 inducers (rifampicin, carbamazepine): reduce hormonal efficacy, increasing pregnancy risk.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs): may alter bleeding patterns.
• Anticonvulsants (phenytoin, phenobarbital): modestly decrease contraceptive effectiveness.
• Herbal supplements (St. John’s wort): may reduce hormone levels.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can increase blood pressure.
• Antibiotics (tetracycline, metronidazole): generally minimal effect but monitor for breakthrough bleeding.